The pursuit of extending human lifespan is increasingly focused on interventions like rapamycin, a drug initially developed as an immunosuppressant. However, a new analysis suggests that the benefits of such treatments may not be universally experienced, and could be described as a “biological lottery,” where individual responses vary significantly.
Researchers have long aimed not only to increase longevity, but also to compress the period of illness and frailty – effectively “squaring the survival curve.” This means reducing the variability in age at death, aiming for fewer premature deaths and a shorter duration of poor health in advanced age. The concept is visualized using a “survival curve,” a graphical representation of the proportion of a population surviving at different ages.
Traditionally, in populations with high rates of early mortality, the survival curve slopes downward gradually. The hope was that treatments like rapamycin, or dietary restriction, would “square” this curve, shifting mortality towards a narrower window at the end of life. However, recent research casts doubt on this expectation.
A comprehensive review of 167 studies across eight non-human species – including fish, mice, rats, and rhesus monkeys – revealed that while lifespan extension was observed, the magnitude of benefit varied considerably among individual animals. This variability challenges the idea of a uniform response to these interventions.
“This suggests that lifespan-extending treatments do not reduce variance and ‘square the survival curve’,” researchers wrote in a study published in the journal Biology Letters. The findings indicate that while these approaches can increase lifespan in some cases, the extent of that increase is unpredictable.
“These approaches can make animals live longer, but the benefits aren’t shared equally. Without more information, the outcome looks like a biological lottery,” explained biologist and study author Tahlia Fulton from The University of Sydney. This suggests that the effectiveness of these interventions is heavily influenced by individual biological factors.
The research highlights that simply demonstrating an average lifespan extension doesn’t tell the whole story. It’s possible for a treatment to increase average lifespan while simultaneously widening the gap between those who benefit significantly and those who see little to no effect. This raises questions about the equitable distribution of benefits from anti-aging therapies.
The study suggests that approaches like dietary restriction or drugs such as rapamycin may be likely beneficial for longevity, but the degree of benefit remains unclear. This reframes how anti-aging breakthroughs are to be interpreted, hinting that future therapies may not produce uniform outcomes.
“Some individuals will be much longer lived, some will be a little longer lived, and some might not live any longer than they would have anyway,” Dr. Fulton told New Scientist. This underscores the complexity of aging and the need for personalized approaches to interventions aimed at extending lifespan.
Researchers are continuing to investigate the relationship between lifespan extension and “healthspan” – the number of years spent in good health. While anti-aging therapies may lead to some individuals living longer, it’s crucial to determine whether those additional years are accompanied by improved quality of life or simply an extension of frailty, and illness.
The recently published PEARL trial, as reported in , demonstrated that low-dose intermittent rapamycin was well-tolerated over a one-year period and resulted in modest changes in biomarkers of biological aging. However, the long-term clinical benefits remain to be established. This trial provides some evidence of rapamycin’s potential, but further research is needed to determine its lasting impact on health and longevity.
The findings emphasize the need for a more nuanced understanding of the factors that influence individual responses to anti-aging interventions. Future research will likely focus on identifying biomarkers that can predict who is most likely to benefit from these treatments, and on developing personalized strategies to maximize their effectiveness. Understanding the “biological lottery” is a critical step towards realizing the promise of extending healthy lifespan for all.
